Discovery and molecular basis of a diverse set of polycomb repressive complex 2 inhibitors recognition by EED

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Li, Ling ^a   Zhang, Hailong ^a   Zhang, Man ^a   Zhao, Mengxi ^a   Feng, Lijian ^a   Luo, Xiao ^a   Gao, Zhenting ^a   Huang, Ying ^a   Ardayfio, Ophelia ^b   Zhang, Ji Hu ^b   Lin, Ying ^a   Fan, Hong ^a   Mi, Yuan ^a   Li, Guobin ^a   Liu, Lei ^a   Feng, Leying ^a   Luo, Fangjun ^a   Teng, Lin ^a   Qi, Wei ^a   Ottl, Johannes ^c   Lingel, Andreas ^b   Bussiere, Dirksen E ^b   Yu, Zhengtian ^a   Atadja, Peter ^a   Lu, Chris ^a   Li, En ^a   Gu, Justin ^a   Zhao, Kehao ^a   more..

^a Novartis Institutes for Biomedical Research   (China)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE H3; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN INHIBITOR; EED PROTEIN, MOUSE; EED226; ENZYME INHIBITOR; SULFONE; TRIAZOLE DERIVATIVE;

ARTICLE; COMPETITIVE BINDING ASSAY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR DOCKING; MOUSE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; DRUG DISCOVERY; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; MOLECULAR DOCKING SIMULATION; POLYCOMB REPRESSIVE COMPLEX 2; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TRIAZOLES;

EID: 85009115484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169855     Document Type: Article

References (40)

1. Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, et al. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood. 2012; 119(5):1318-9. doi: 10.1182/blood-2011-07-365213 PMID: 22308284
2. Majer CR, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 2012; 586(19):3448-51. doi: 10.1016/j.febslet.2012. 07.066 PMID: 22850114
3. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(8):2989-94. doi: 10.1073/pnas.1116418109 PMID: 22323599
4. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature genetics. 2010; 42(2):181-5. doi: 10.1038/ng.518 PMID: 20081860
5. Ott HM, Graves AP, Pappalardi MB, Huddleston M, Halsey WS, Hughes AM, et al. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation. Molecular cancer therapeutics. 2014; 13 (12):3062-73. doi: 10.1158/1535-7163.MCT-13-0876 PMID: 25253781
6. Wigle TJ, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM, et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 2011; 585(19):3011-4. doi: 10.1016/j.febslet.2011.08.018 PMID: 21856302
7. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011; 117(8):2451-9. doi: 10.1182/blood-2010-11-321208 PMID: 21190999
8. Campbell JE, Kuntz KW, Knutson SK, Warholic NM, Keilhack H, Wigle TJ, et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS medicinal chemistry letters. 2015; 6 (5):491-5. doi: 10.1021/acsmedchemlett.5b00037 PMID: 26005520
9. Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan EY, Sandy P, Busby J, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chemistry & biology. 2013; 20(11):1329-39.
10. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Molecular cancer therapeutics. 2014; 13(4):842-54. doi: 10.1158/1535-7163.MCT-13-0773 PMID: 24563539
11. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(52):21360-5. doi: 10.1073/pnas.1210371110 PMID: 23236167
12. Verma SK, Tian X, La France LV, Duquenne C, Suarez DP, Newlander KA, et al. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS medicinal chemistry letters. 2012; 3(12):1091-6. doi: 10.1021/ml3003346 PMID: 24900432
13. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell. 2004; 15(1):57-67. doi: 10.1016/j.molcel.2004.06.020 PMID: 15225548
14. Montgomery ND, Yee D, Chen A, Kalantry S, Chamberlain SJ, Otte AP, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol. 2005; 15(10):942-7. doi: 10.1016/j.cub.2005.04.051 PMID: 15916951
15. Obier N, Lin Q, Cauchy P, Hornich V, Zenke M, Becker M, et al. Polycomb protein EED is required for silencing of pluripotency genes upon ESC differentiation. Stem Cell Rev. 2015; 11(1):50-61. doi: 10. 1007/s12015-014-9550-z PMID: 25134795
16. Ciferri C, Lander GC, Maiolica A, Herzog F, Aebersold R, Nogales E. Molecular architecture of human polycomb repressive complex 2. Elife. 2012; 1:e00005. doi: 10.7554/eLife.00005 PMID: 23110252
17. Brooun A, Gajiwala KS, Deng YL, Liu W, Bolanos B, Bingham P, et al. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Nat Commun. 2016; 7:11384. doi: 10.1038/ncomms11384 PMID: 27122193
18. Jiao L, Liu X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science. 2015; 350(6258):aac4383. doi: 10.1126/science.aac4383 PMID: 26472914
19. Justin N, Zhang Y, Tarricone C, Martin SR, Chen S, Underwood E, et al. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun. 2016; 7:11316. doi: 10.1038/ncomms11316 PMID: 27121947
20. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ 3rd, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature. 2009; 461(7265):762-7. doi: 10.1038/nature08398 PMID: 19767730
21. Han Z, Xing X, Hu M, Zhang Y, Liu P, Chai J. Structural basis of EZH2 recognition by EED. Structure. 2007; 15(10):1306-15. doi: 10.1016/j.str.2007.08.007 PMID: 17937919
22. Xu C, Min J. Structure and function of WD40 domain proteins. Protein Cell. 2011; 2(3):202-14. doi: 10. 1007/s13238-011-1018-1 PMID: 21468892
23. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nature chemical biology. 2013; 9(10):643-50. doi: 10.1038/nchembio.1331 PMID: 23974116
24. Qi W, Zhao K, Gu J, Huang Y, Wang Y, Zhang H, Zhang M, Zhang J, Yu Z, Li L, Teng L, Chuai S, Zhang C, Zhao M, Chan HM, Chen Z, Fang D, Fei Q, Feng LY, Feng LJ, Gao Y, Ge H, Ge XJ, Li G, Lingel A, Lin Y, Liu Y, Luo F, Shi M, Wang L, Wang Z, Yu Y, Zeng J, Zeng C, Zhang L, Zhang Q, Zhou S, Oyang C, Atadja P, Li E. An allosteric PRC2 inhibitor targeting EED H3K27me3 binding pocket. Nature Chemical Biology 2016; In press.
25. Li S, Gu XJ, Hao Q, Fan H, Li L, Zhou S, et al. A liquid chromatography/mass spectrometry-based generic detection method for biochemical assay and hit discovery of histone methyltransferases. Analytical biochemistry. 2013; 443(2):214-21. doi: 10.1016/j.ab.2013.08.029 PMID: 24018340
26. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26.
27. Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):125-32.
28. Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):22-5. doi: 10.1107/S0907444909042589 PMID: 20057045
29. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. doi: 10.1107/S0907444904019158 PMID: 15572765
30. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):355-67. doi: 10.1107/S0907444911001314 PMID: 21460454
31. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, Bricogne G. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2210-21. doi: 10.1107/S0907444904016427 PMID: 15572774
32. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. Journal of applied crystallography. 1993; 26(2):283-91.
33. Quinn AM, Bedford MT, Espejo A, Spannhoff A, Austin CP, Oppermann U, et al. A homogeneous method for investigation of methylation-dependent protein-protein interactions in epigenetics. Nucleic Acids Res. 2010; 38(2):e11. doi: 10.1093/nar/gkp899 PMID: 19897549
34. Wigle TJ, Herold JM, Senisterra GA, Vedadi M, Kireev DB, Arrowsmith CH, et al. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. J Biomol Screen. 2010; 15(1):62-71. doi: 10.1177/1087057109352902 PMID: 20008125
35. Santiago C, Nguyen K, Schapira M. Druggability of methyl-lysine binding sites. J Comput Aided Mol Des. 2011; 25(12):1171-8. doi: 10.1007/s10822-011-9505-2 PMID: 22146969
36. Wu H, Zeng H, Dong A, Li F, He H, Senisterra G, et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PloS one. 2013; 8(12):e83737. doi: 10.1371/journal.pone.0083737 PMID: 24367611
37. Kouzarides T. Chromatin modifications and their function. Cell. 2007; 128(4):693-705. doi: 10.1016/j. cell.2007.02.005 PMID: 17320507
38. Musselman CA, Khorasanizadeh S, Kutateladze TG. Towards understanding methyllysine readout. Biochim Biophys Acta. 2014; 1839(8):686-93. doi: 10.1016/j.bbagrm.2014.04.001 PMID: 24727128
39. Huang Y, Zhang J, Yu Z, Zhang H, Wang Y, Lingel A, Qi W, Gu J, Zhao K, Shultz MD, Wang L, Fu X, Sun Y, Zhang Q, Jiang X, Zhang J, Zhang C, Li L, Zeng J, Feng L, Zhang C, Liu Y, Zhang M, Zhang L, Zhao M, Gao Z, Liu X, Fang D, Guo H, Mi Y, Gabriel T DM, Atadja P, Oyang C. Discovery of first-inclass, potent and orally bioavailable EED inhibitors with robust anti-cancer efficacy. Submittd to J Med Chem. 2016.
40. Lingel A, Sendzik M, Huang Y, Shultz MD, Cantwell J, Dillon MP, et al. Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase. J Med Chem. 2016.